Home / Assets / Boston Scientific (BSX)
Stock

The best indicator for Boston Scientific (BSX)

We backtested 20 indicators across daily, weekly and hourly charts on real Boston Scientific (BSX) history. Here's what actually worked — risk-adjusted, out-of-sample, with costs.

Volatility · Weekly

Bollinger Breakout

On the weekly chart, this is the strongest risk-adjusted edge we found for Boston Scientific (BSX) over ~34.2 years — trailing buy-and-hold by 1.0% CAGR.

6.2%
CAGR
0.43
Sharpe
-48.4%
Max DD
53.6%
Win rate
3.84
Profit factor
-1.0%
vs Buy&Hold
Best by timeframe

The winner on each chart

Weekly
Bollinger Breakout
-1.0% · Sharpe 0.43
Daily
EMA 50/200 Cross
0.0% · Sharpe 0.41
Full results

Every indicator, ranked

Ranked by Sharpe (risk-adjusted return). Hypothetical, fees included.

#IndicatorTFCAGRSharpeMax DDWinTradesvs B&H
1Bollinger Breakout Weekly6.2%0.43-48.4%53.6%28-1.0%
2EMA 50/200 Cross Daily7.4%0.41-77.9%38.9%180.0%
3Donchian Midline Weekly7.5%0.41-70.4%41.9%930.3%
4EMA 20/50 Cross Weekly9.4%0.49-67.2%33.3%122.2%
5Donchian Breakout Weekly6.1%0.38-74.2%48.1%27-1.1%
6Rate of Change Weekly6.1%0.37-76.8%40.8%103-1.0%
7EMA-10 Trend Weekly5.9%0.36-61.4%42.7%157-1.2%
8ADX / DMI Weekly4.6%0.34-53.7%50.0%50-2.6%
9EMA 20/50 Cross Daily5.4%0.33-82.3%37.2%78-2.0%
10RSI Trend (>50) Weekly5.1%0.33-72.3%43.8%89-2.0%
11Bollinger Mean-Reversion Daily4.3%0.3-58.8%69.9%146-3.1%
12MACD Weekly4.5%0.3-85.7%49.4%77-2.7%
13SMA 50/200 Cross Daily3.5%0.26-89.8%44.0%25-3.9%
14ADX / DMI Daily3.0%0.25-67.2%43.3%210-4.4%

= held up out-of-sample. Hypothetical, costs included. See methodology.

What this means

For Boston Scientific (BSX), Bollinger Breakout on the weekly timeframe gave the best balance of return and risk in our test. It still trailed buy-and-hold on raw return — but remember: this is a hypothetical backtest of a standard rule, not a recommendation. Markets change. See the methodology and disclaimer.

More stock

Free · no spam

Get the weekly edge report

The best-performing indicator per asset, what changed this week, and the honest caveats — straight to your inbox.